Pharmacogenetics · 2001 · 68 citations · 19 references
MedicinePharmacologyPsychiatryNeuropharmacologyPsychiatric PharmacotherapyPsychopharmacologyAntipsychotic PharmacologyAntipsychotic PharmacotherapyAntipsychotic TherapyPsychiatric GeneticsSerotonergic PharmacologyTreatment-resistant Psychiatric DisordersAntipsychotic PharmacogenomicsGenetic Risk VariantsLow Body Mass IndexSchizophrenia GeneticsSerotonin Receptor PolymorphismsSerotonin Transporter FunctionSerotonin Transporter Gene VariantsSerotonin Transporter Polymorphism
Clozapine-induced weight gain may impair health and affect patient compliance. The aim of this study is to investigate the relationship between the genetic variants of the serotonin system and clozapine-induced body weight change (BWC). Ninety-three treatment-resistant schizophrenic patients were weighed monthly for 4 months during clozapine treatment. At the conclusion of treatment, patients had gained an average of 2.4 kg body weight, with BWC ranging from -17.5 to +12.9 kg. The levels of the serotonin transporter variants, serotonin 2A, serotonin 2C and serotonin 6, demonstrated no statistically significant relationship to BWC. Patients with a lower initial body mass index demonstrated a greater weight gain associated with clozapine treatment. Further exploration of the neurotransmitters implicated in the antipsychotic-induced BWC is important in order to reduce the morbidity and noncompliance associated with weight gain.
19
Allelic Variation of Human Serotonin Transporter Gene Expression
Armin Heils, Andreas Teufel, Susanne Petri et al. · Journal of Neurochemistry · 1996 · 2.2K citations
Receptor pharmacology of neuroleptics: relation to clinical effects.
Elliott Richelson · PubMed · 1999 · 307 citations
An overview of the mechanism of action of clozapine.
Herbert Y. Meltzer · PubMed · 1994 · 288 citations